Zalypsis (BioDeep_00000838420)
代谢物信息卡片
化学式: C37H38F3N3O8 (709.2610864000001)
中文名称:
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CC1=CC2=C(C3C4CC5=C(C(=C6C(=C5C(N4C(C(C2)N3C)O)CNC(=O)C=CC7=CC(=CC=C7)C(F)(F)F)OCO6)C)OC(=O)C)C(=C1OC)O
InChI: InChI=1S/C37H38F3N3O8/c1-17-11-21-13-25-36(47)43-24(30(42(25)4)28(21)31(46)32(17)48-5)14-23-29(35-34(49-16-50-35)18(2)33(23)51-19(3)44)26(43)15-41-27(45)10-9-20-7-6-8-22(12-20)37(38,39)40/h6-12,24-26,30,36,46-47H,13-16H2,1-5H3,(H,41,45)/b10-9+/t24-,25-,26-,30-,36-/m0/s1
描述信息
C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C2842 - DNA Binding Agent
同义名列表
1 个代谢物同义名
数据库引用编号
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Ana-Alicia López-Iglesias, Lorena González-Méndez, Laura San-Segundo, Ana B Herrero, Susana Hernández-García, Montserrat Martín-Sánchez, Norma C Gutiérrez, Teresa Paíno, Pablo Avilés, María-Victoria Mateos, Jesús F San-Miguel, Mercedes Garayoa, Enrique M Ocio. Synergistic DNA-damaging effect in multiple myeloma with the combination of zalypsis, bortezomib and dexamethasone.
Haematologica.
2017 01; 102(1):168-175. doi:
10.3324/haematol.2016.146076. [PMID: 27540138] - J Capdevila, S Clive, E Casado, C Michie, A Piera, E Sicart, M J Carreras, C Coronado, C Kahatt, A Soto Matos-Pita, C Fernandez Teruel, M Siguero, M Cullell-Young, J Tabernero. A phase I pharmacokinetic study of PM00104 (Zalypsis) administered as a 24-h intravenous infusion every 3 weeks in patients with advanced solid tumors.
Cancer chemotherapy and pharmacology.
2013 May; 71(5):1247-54. doi:
10.1007/s00280-013-2119-8. [PMID: 23455428] - Mario González-Sales, Belén Valenzuela, Carlos Pérez-Ruixo, Carlos Fernández Teruel, Bernardo Miguel-Lillo, Arturo Soto-Matos, Juan Jose Pérez-Ruixo. Population pharmacokinetic-pharmacodynamic analysis of neutropenia in cancer patients receiving PM00104 (Zalypsis(®)).
Clinical pharmacokinetics.
2012 Nov; 51(11):751-64. doi:
10.1007/s40262-012-0011-z. [PMID: 23055348] - Carlos Pérez-Ruixo, Belén Valenzuela, Carlos Fernández Teruel, Mario González-Sales, Bernardo Miguel-Lillo, Arturo Soto-Matos, Juan José Pérez-Ruixo. Population pharmacokinetics of PM00104 (Zalypsis(®)) in cancer patients.
Cancer chemotherapy and pharmacology.
2012 Jan; 69(1):15-24. doi:
10.1007/s00280-011-1644-6. [PMID: 21590449] - Enrique M Ocio, Patricia Maiso, Xi Chen, Mercedes Garayoa, Stela Alvarez-Fernández, Laura San-Segundo, David Vilanova, Lucía López-Corral, Juan C Montero, Teresa Hernández-Iglesias, Enrique de Alava, Carlos Galmarini, Pablo Avilés, Carmen Cuevas, Jesús F San-Miguel, Atanasio Pandiella. Zalypsis: a novel marine-derived compound with potent antimyeloma activity that reveals high sensitivity of malignant plasma cells to DNA double-strand breaks.
Blood.
2009 Apr; 113(16):3781-91. doi:
10.1182/blood-2008-09-177774. [PMID: 19020308] - Jianming Yin, Pablo Aviles, William Lee, Carl Ly, Maria Jose Guillen, Simon Munt, Carmen Cuevas, Glynn Faircloth. Development of a liquid chromatography/tandem mass spectrometry assay for the quantification of PM00104, a novel antineoplastic agent, in mouse, rat, dog, and human plasma.
Rapid communications in mass spectrometry : RCM.
2005; 19(5):689-95. doi:
10.1002/rcm.1848. [PMID: 15702485]